Maserati Says People Have a 'Bad Feeling' About Electric Supercars
canceled the fully electric MC20
after realizing customers 'are very keen on driving powerful ICE engines.' That's according to an official statement sent to
Motor1
by a company spokesperson back in March. With that in mind, it's no surprise the Modena-based automaker is now channeling its efforts into gas-powered models.
Davide Danesin, Head of Engineering, told
Autocar
that some people have a 'bad feeling' about supercars equipped with a battery. We'd add that the sentiment likely extends to most performance-oriented cars, from affordable hot hatches to seven-figure hypercars. He went on to admit that 'there are still customers looking for pure mechanical cars,' as evidencened by high-end buyers who had no interest in an EV version of the MC20.
These concerns largely stem from the additional hardware EVs require, which increases complexity, adds weight, and introduces all the downsides that come with it. As a result, the plan is to give people what they want: a pure ICE experience via the company's Nettuno V-6. Beyond that, a manual gearbox could even make a surprising return.
Maserati hasn't sold a three-pedal car since the mid-2000s. Yet, Danesin sees a stick shift as a real possibility for a limited-run model: 'By doing a purely mechanical car, it does make sense to have a mechanical gearbox with a shifter. It fulfils perfectly our approach and the mindset. So honestly, I think one day we'll do it.'
Alfa Romeo and Maserati CEO Santo Ficili reiterates that the two Italian brands will
collaborate more closely
in the future, hinting at the prospect of a jointly developed gasoline supercar. The tie-up would follow the 33 Stradale, which partially borrowed the carbon tub and aluminum subframes at both ends from the MC20.
Autocar
speculates that a Maserati-branded supercar would likely be a Granturismo-based GT featuring an upgraded version of the twin-turbo 3.0-liter engine, delivering more than the 621 hp available in the MC20 and its
MCPura
successor. The added power would likely come without any electric assistance.
An equivalent Alfa Romeo is reportedly also in the pipeline, helping to achieve economies of scale and make a solid business case. However, the brand's marketing boss, Cristiano Fiorio, recently said a follow-up to the 33 Stradale shouldn't be rushed, as
volume-oriented models are the current priority
.
We shouldn't fault automakers for channeling resources into hybrids and EVs. Increasingly strict emissions regulations make it harder to justify investing in gas-powered sports cars, especially those with large-displacement engines. Another challenge facing car companies and their customers is the higher taxation on pure ICE vehicles in certain parts of the world, particularly in Europe.
To give you a weird example: the BMW M3 is €17,350 ($20,000)
more expensive
than the M5 in Ireland, due to the latter's lower emissions
(at least on paper)
from its plug-in hybrid setup.
Catch Up With Maserati:
Maserati Is Not for Sale
Maserati Sales Aren't Doing Great
Source:
Autocar
Share this Story
X
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Where Morgan Stanley is looking for value after powerful rebound in U.S. stocks
The U.S. stock market mostly added to its big rebound from its April low after President Donald Trump announced on Sunday a trade deal with the European Union, amid worries over rich valuations. Investors have been rotating into cyclical stocks from defensive equities amid signs of a resilient economy and confidence in corporate earnings, Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, said in a note Monday. The rotation was partly amplified by optimism over the One Big Beautiful Bill Act suggesting 'a capex boom and cyclical recovery in the second half of 2025 through 2026, potentially further fueled by Federal Reserve rate cuts,' according to her note. Social Security wants to make a change that would cause 3.4 million more people to have to visit its field offices We're in our 70s with a $260K mortgage at 3% interest and $1.6 million in savings. Should we pay off our house in full? Why the man behind 'The Hater's Guide to the AI Bubble' thinks Wall Street's hottest trade will go bust The most important woman in bonds says investors now have unrealistic expectations The stock market has rebounded from the early April selloff sparked by Trump's announcement of 'liberation day' tariffs. The market recovered after the White House paused the tariffs and investors perceived positive developments as the U.S. worked on trade deals. The S&P 500 SPX closed at a record high each day of last week, ahead of Trump's meeting Sunday with European Commission President Ursula von der Leyen in Scotland on trade. They reached an agreement under which the European Union will pay 15% tariffs for most goods imported to the U.S. That followed other trade deals announced last week, including with Japan. Read: S&P 500 scores 5th straight record high ahead of Europe-U.S. trade meeting 'The equity market's powerful recovery from the tariff uncertainty bear market has been driven by multiple factors—technical, positional and fundamental,' Shalett said. 'Oversold conditions and derisking set the stage for a strong pivot back to equities once the 90-day reciprocal tariff pause was announced, while economic resilience supported earnings confidence.' With the S&P 500 again approaching historically high valuations, Morgan Stanley Wealth Management sees investment opportunities in the healthcare sector amid the recent rotation into cyclical stocks, according to Shalett. 'Health care—namely, medical equipment, devices and supplies, and distribution logistics —remains one of our favored fishing ponds for value,' she said. Healthcare XX:SP500.35 has been the worst-performing S&P 500 sector in 2025, according to a Bespoke Investment Group note emailed Monday ahead of the U.S. stock market's opening bell. Consumer discretionary XX:SP500.25 was the only other sector in the red year to date, while six of the S&P 500 index's 11 sectors were beating the index, the Bespoke chart above shows. 'Yes, technology is one of the sectors that's ahead of the S&P 500, but other non-tech sectors like industrials, utilities, financials, and materials have also outperformed' this year, Bespoke said in the note. The S&P 500, which has an outsize weight to Big Tech stocks, has climbed 8.6% in 2025 through Monday. In a sign that this year's rally hasn't been just about Big Tech, shares of the Invesco S&P 500 Equal Weight ETF RSP, an exchange-traded fund that equally weights stocks in the index, has risen 6.5% this year over the same stretch, FactSet data show. Meanwhile, U.S. businesses have been reporting this month their latest quarterly earnings, with results from Big Tech companies Meta Platforms Inc. META, Microsoft Corp. MSFT, Inc. AMZN and Apple Inc. AAPL scheduled for this week, according to the Bespoke note. 'We hope you had a restful weekend, because the last four days of July and the first trading day of August are going to be jam-packed with earnings and economic data,' Bespoke said. The Federal Reserve will wrap up its two-day meeting on monetary policy on Wednesday with a decision on where it's setting interest rates. The U.S. jobs report for July will be released Friday, while data on manufacturing and consumer sentiment will be released that same day. More imminently, Tuesday's U.S. economic calendar includes fresh reports on areas such as job openings and consumer confidence. The U.S. stock market closed mostly higher Monday, with the S&P 500 eking out a gain of less than 0.1% to notch a sixth straight record peak. The tech-heavy Nasdaq Composite COMP rose 0.3% to book a fresh all-time closing high, while the Dow Jones Industrial Average DJIA slipped 0.1%. The S&P 500 ended Monday up 28.2% from its April 8 low, according to Dow Jones Market Data. 'The stock market's stunning rebound and resilience have again emboldened equity investors,' said Shalett, who pointed to their optimism about 'Goldilocks' economic conditions. But she cautioned against 'buying the market' through the passive S&P 500 index, saying 'complacency is elevated, and valuations are rich.' Shalett said to consider stocks with 'earnings and cash-flow upside-surprise potential,' which may be found among 'select tech hardware and services names, industrials, financials, energy and parts of health care that are policy beneficiaries amid higher structural volatility and real rates, and a weak U.S. dollar.' Comcast could see its heaviest internet-subscriber losses ever. Then what? How stock-market investors should trade what could be a historic Fed dissent on Wednesday Royal Caribbean stock gets rocked despite higher demand for cruises. Here's why. 'I have Type 1 diabetes': I'm 64 with a $1.3 million 401(k). Is it too late for long-term-care insurance? Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Santander's quarterly profit hits record as fees offset weak Mexico and Brazil
By Jesús Aguado MADRID (Reuters) -Santander on Wednesday said its second-quarter net profit rose 7% on the year as higher fees and lower provisions offset a decline in Brazil and Mexico due to currency depreciations. The euro zone's largest bank by market value reported a record fifth consecutive quarterly net profit, reaching 3.43 billion euros ($3.96 billion) in the April to June period, slightly exceeding analysts' expectations of 3.36 billion euros from a Reuters poll. It also announced a new share buyback of 1.7 billion euros set to begin on Thursday, representing around 25% of the group's profit in the first half of 2025. The buyback is part of its previously announced 10 billion euros programme for 2025 and 2026. The bank has benefited in the past from higher interest rates, while growth in key Latin American markets such as Brazil has given it an edge over more Europe-dependent rivals. However, quarterly net profit in Mexico, its fourth-biggest market, fell 6.8% against a backdrop of geopolitical risks stemming from U.S. trade tariffs, particularly in that market, due to the depreciation of the Mexican peso, while net profit in Brazil, its second-biggest market after Spain, fell 16%. A 2.4% rise in fees and a decline of 3.2% in provisions helped lift Santander's return on tangible equity ratio (ROTE), after the impact of additional Tier 1 (AT1) capital instruments, a measure of profitability, to 16.2% in the quarter, compared with 15.8% at the end of March. It said it was on track to meet its target of around 16.5% this year. It said it was also on its path to meet its full-year revenue target of around 62 billion euros, while its core Tier-1 capital ratio rose 10 basis points from the previous quarter to 13% by end-June, at the top end of the bank's operating range of 12% to 13% after achieving the 2025 target ahead of schedule. ($1 = 0.8669 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
